^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations

Published date:
06/01/2020
Excerpt:
One patient with V659E responded well to ERBB2 inhibitor lapatinib plus capecitabine as well as subsequent afatinib treatment upon progression.
DOI:
10.1002/1878-0261.12733